Poon KA et al. |
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. |
2013 |
Toxicol. Appl. Pharmacol. |
pmid:24035823
|
|
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. |
2013 |
Med Lett Drugs Ther |
pmid:24043217
|
Sendur MA et al. |
Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab? |
2013 Jul-Sep |
J BUON |
pmid:24065505
|
Bartsch R et al. |
Breast cancer brain metastases responding to primary systemic therapy with T-DM1. |
2014 |
J. Neurooncol. |
pmid:24065570
|
Bourdeanu L and Luu T |
Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer. |
2013 |
Clin J Oncol Nurs |
pmid:24080060
|
Kümler I et al. |
A systematic review of dual targeting in HER2-positive breast cancer. |
2014 |
Cancer Treat. Rev. |
pmid:24080156
|
Mihály Z and Gyõrffy B |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response]. |
2013 |
Magy Onkol |
pmid:24107820
|
Dank M and Tõkés T |
[Monoclonal antibody therapy in breast cancer]. |
2013 |
Magy Onkol |
pmid:24107821
|
Venghateri JB et al. |
Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site. |
2013 |
PLoS ONE |
pmid:24124473
|
Ribrag V et al. |
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. |
2014 |
Clin. Cancer Res. |
pmid:24132920
|
Krop I and Winer EP |
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. |
2014 |
Clin. Cancer Res. |
pmid:24135146
|
Barroso-Sousa R et al. |
Biological therapies in breast cancer: common toxicities and management strategies. |
2013 |
Breast |
pmid:24144949
|
De Angelis C et al. |
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. |
2013 May-Jun |
Tumori |
pmid:24158083
|
Gao Y et al. |
Enhancement of ansamitocin P-3 production in Actinosynnema pretiosum by a synergistic effect of glycerol and glucose. |
2014 |
J. Ind. Microbiol. Biotechnol. |
pmid:24174216
|
Welslau M et al. |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. |
2014 |
Cancer |
pmid:24222194
|
Palomba ML and Younes A |
In the spotlight: a novel CD37 antibody-drug conjugate. |
2013 |
Blood |
pmid:24235129
|
Azvolinsky A |
Conjugating antibodies to cytotoxic agents: getting the best of both worlds? |
2013 |
J. Natl. Cancer Inst. |
pmid:24244034
|
Haddley K |
Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. |
2013 |
Drugs Today |
pmid:24308017
|
Drachman JG and Senter PD |
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. |
2013 |
Hematology Am Soc Hematol Educ Program |
pmid:24319196
|
Gibiansky L and Gibiansky E |
Target-mediated drug disposition model and its approximations for antibody-drug conjugates. |
2014 |
J Pharmacokinet Pharmacodyn |
pmid:24322877
|
|
T-DM1 aids patients with advanced breast cancer. |
2013 |
Cancer Discov |
pmid:24327714
|
Kim M et al. |
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. |
2014 |
Curr. Opin. Obstet. Gynecol. |
pmid:24335887
|
Berdeja JG |
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. |
2014 |
Front Biosci (Landmark Ed) |
pmid:24389179
|
Yue W et al. |
Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical. |
2013 |
J. Exp. Ther. Oncol. |
pmid:24416991
|
Beck A and Reichert JM |
Antibody-drug conjugates: present and future. |
2014 Jan-Feb |
MAbs |
pmid:24423577
|
Panowski S et al. |
Site-specific antibody drug conjugates for cancer therapy. |
2014 Jan-Feb |
MAbs |
pmid:24423619
|
Thery JC et al. |
Resistance to human epidermal growth factor receptor type 2-targeted therapies. |
2014 |
Eur. J. Cancer |
pmid:24462377
|
Wang J et al. |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. |
2014 |
Clin. Pharmacol. Ther. |
pmid:24488143
|
Lianos GD and Roukos DH |
From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. |
2014 |
Future Oncol |
pmid:24490597
|
Whiteman KR et al. |
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. |
2014 Mar-Apr |
MAbs |
pmid:24492307
|
Carlson JA et al. |
Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. |
2014 |
Neuro-oncology |
pmid:24497407
|
Perrino E et al. |
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. |
2014 |
Cancer Res. |
pmid:24520075
|
Lieberman P and Castells M |
Desensitization to chemotherapeutic agents. |
2014 Jan-Feb |
J Allergy Clin Immunol Pract |
pmid:24565784
|
Patel KC et al. |
Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. |
2014 |
Am J Health Syst Pharm |
pmid:24644113
|
Yan M et al. |
HER2 aberrations in cancer: implications for therapy. |
2014 |
Cancer Treat. Rev. |
pmid:24656976
|
Dhillon S |
Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. |
2014 |
Drugs |
pmid:24659374
|
|
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. |
2013 |
Med Lett Drugs Ther |
pmid:24662957
|
Diessner J et al. |
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). |
2014 |
Cell Death Dis |
pmid:24675467
|
Baron JM et al. |
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. |
2015 |
J Oncol Pharm Pract |
pmid:24682654
|
Golfier S et al. |
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. |
2014 |
Mol. Cancer Ther. |
pmid:24714131
|
Miller KD et al. |
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. |
2014 |
J. Clin. Oncol. |
pmid:24733796
|
Force J et al. |
Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. |
2016 |
J. Clin. Oncol. |
pmid:24778392
|
Krop IE et al. |
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. |
2014 |
Lancet Oncol. |
pmid:24793816
|
Gnant M et al. |
HER2-positive breast cancer: a new piece of the puzzle. |
2014 |
Lancet Oncol. |
pmid:24793817
|
Giordano SH et al. |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. |
2014 |
J. Clin. Oncol. |
pmid:24799465
|
Kolarich AR et al. |
Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. |
2014 |
Acta Oncol |
pmid:24834794
|
Stinchcombe TE |
Novel formulations and new mechanisms of delivering chemotherapy. |
2014 |
Am Soc Clin Oncol Educ Book |
pmid:24857128
|
Wright J |
Nanotechnology: Deliver on a promise. |
2014 |
Nature |
pmid:24870822
|
Kim MT et al. |
Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. |
2014 |
Bioconjug. Chem. |
pmid:24873191
|
Amiri-Kordestani L et al. |
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. |
2014 |
Clin. Cancer Res. |
pmid:24879797
|
Tripathy D et al. |
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. |
2014 |
BMC Cancer |
pmid:24885258
|
Barok M et al. |
Trastuzumab emtansine: mechanisms of action and drug resistance. |
2014 |
Breast Cancer Res. |
pmid:24887180
|
Perez EA et al. |
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. |
2014 |
Breast Cancer Res. |
pmid:24887458
|
English DP et al. |
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. |
2014 |
Cancer Med |
pmid:24890382
|
Cretella D et al. |
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. |
2014 |
Mol. Cancer |
pmid:24898067
|
Martin K et al. |
The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. |
2014 |
Cancer Immunol. Immunother. |
pmid:24906866
|
Villanueva MT |
Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer. |
2014 |
Nat Rev Clin Oncol |
pmid:24913372
|
Bender B et al. |
A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. |
2014 |
AAPS J |
pmid:24917179
|
Sibaud V et al. |
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. |
2014 |
Breast Cancer Res. Treat. |
pmid:24929675
|
Lu D et al. |
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. |
2014 |
Cancer Chemother. Pharmacol. |
pmid:24939213
|
Lambert JM and Chari RV |
Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. |
2014 |
J. Med. Chem. |
pmid:24967516
|
Yu L et al. |
Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. |
2014 |
Int. J. Gynecol. Cancer |
pmid:24987913
|
Diéras V et al. |
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. |
2014 |
J. Clin. Oncol. |
pmid:25024070
|
Corrigan PA et al. |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. |
2014 |
Ann Pharmacother |
pmid:25082874
|
Tanz R et al. |
[Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. |
2014 Jul-Aug |
Bull Cancer |
pmid:25091656
|
White C |
NICE confirms advanced breast cancer drug is too expensive for NHS. |
2014 |
BMJ |
pmid:25106642
|
Prota AE et al. |
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:25114240
|
Leal M et al. |
Antibody-drug conjugates: an emerging modality for the treatment of cancer. |
2014 |
Ann. N. Y. Acad. Sci. |
pmid:25123209
|
Torres S et al. |
Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. |
2014 |
BMJ Case Rep |
pmid:25123575
|
Hussar DA |
New drugs 2014, part 3. |
2014 |
Nursing |
pmid:25153167
|
Wada R et al. |
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. |
2014 |
Cancer Chemother. Pharmacol. |
pmid:25186956
|
Field JJ et al. |
A previously undescribed tubulin binder. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:25187564
|
Pillow TH et al. |
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. |
2014 |
J. Med. Chem. |
pmid:25191794
|
Teplinsky E and Muggia F |
Targeting HER2 in ovarian and uterine cancers: challenges and future directions. |
2014 |
Gynecol. Oncol. |
pmid:25220628
|
Feng L et al. |
Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. |
2014 |
Clin. Cancer Res. |
pmid:25294907
|
Vigne E and Sassoon I |
[The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules]. |
2014 |
Med Sci (Paris) |
pmid:25311020
|
Yamamoto H et al. |
Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. |
2015 |
Jpn. J. Clin. Oncol. |
pmid:25332421
|
Mancuso L et al. |
Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach. |
2014 |
Chemistry |
pmid:25346489
|
Krop IE et al. |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. |
2015 |
Ann. Oncol. |
pmid:25355722
|
Uppal H et al. |
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). |
2015 |
Clin. Cancer Res. |
pmid:25370470
|
Nicoletti R et al. |
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. |
2015 |
Clin. Exp. Metastasis |
pmid:25398397
|
Sibaud V et al. |
T-DM1-related telangiectasias: a potential role in secondary bleeding events. |
2015 |
Ann. Oncol. |
pmid:25403586
|
Bhardwaj AS et al. |
A case of vasculitis in a breast cancer patient treated with T-DM1. |
2014 |
Semin. Oncol. |
pmid:25440614
|
Coussy F et al. |
[New targeted therapies in breast cancer]. |
2014 |
Gynecol Obstet Fertil |
pmid:25442825
|
Kalsi R et al. |
Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. |
2015 |
Clin. Breast Cancer |
pmid:25454740
|
Fan Y et al. |
Process optimization with alternative carbon sources and modulation of secondary metabolism for enhanced ansamitocin P-3 production in Actinosynnema pretiosum. |
2014 |
J. Biotechnol. |
pmid:25456055
|
Mang Y et al. |
Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. |
2015 |
Int. Immunopharmacol. |
pmid:25467246
|
Montemurro F |
HER2 expression and efficacy of T-DM1. |
2014 |
Breast Cancer Res. |
pmid:25472666
|
Kusari S et al. |
Endophytes are hidden producers of maytansine in Putterlickia roots. |
2014 |
J. Nat. Prod. |
pmid:25478947
|
Carneiro BA et al. |
Emerging therapeutic targets in bladder cancer. |
2015 |
Cancer Treat. Rev. |
pmid:25498841
|
Li T et al. |
Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. |
2015 |
Appl. Biochem. Biotechnol. |
pmid:25564203
|
Lai KC et al. |
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. |
2015 |
Pharm. Res. |
pmid:25630819
|
Wiggins B et al. |
Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. |
2015 |
J Pharm Sci |
pmid:25631158
|
Foglietta J et al. |
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. |
2015 |
Ann. Oncol. |
pmid:25632067
|
Ahmed S et al. |
HER2-directed therapy: current treatment options for HER2-positive breast cancer. |
2015 |
Breast Cancer |
pmid:25634227
|
Goldmacher VS et al. |
Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. |
2015 |
Mol. Pharm. |
pmid:25635630
|
Goldmacher VS et al. |
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. |
2015 |
PLoS ONE |
pmid:25671541
|
Marcoux J et al. |
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. |
2015 |
Protein Sci. |
pmid:25694334
|
Krop IE et al. |
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. |
2015 |
J. Clin. Oncol. |
pmid:25713436
|
Fishkin N |
Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. |
2015 |
Mol. Pharm. |
pmid:25738231
|